Considering that miRNAs were found involved in the regulation of anti-cancer immune response [21, 32–36], we developed a miRNA-related expression signature, which could be a good addition to PD-L1 or MSI-H and help identify CRC patients with different TMB levels. The gene discussed is CD274; the disease is cancer.